Want to join the conversation?
$VRX said it agreed to divest all North American commercialization rights to Ruconest (recombinant human C1 esterase inhibitor) to Pharming Group. Pharming will pay $VRX aggregate consideration of up to $125MM, including upfront fee of $60MM payable upon closing and certain sales-based milestone payments of up to $65MM.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.